RUTHERFORD, NJ--(Marketwire - August 02, 2012) - Cancer Genetics, Inc. (CGI), a leader in cancer diagnostics, announces that it has been selected by Roche Servicios S.A., an affiliate of the Swiss drug maker Roche based in Costa Rica, as its partner for cancer testing. Under this service agreement, CGI performs highly complex testing intended to provide information for the diagnosis and prognosis of cancer patients. Services provided by CGI help Roche Servicios in delivering quality results to clinicians based in 14 different locations covering Central America and Caribbean Islands. The assessed biomarkers are related to the most prevalent cancers in those regions which also correspond to the primary cause of cancer related mortality. With this partnership, Roche Servicios S.A. and CGI join their efforts to commit to personalized medicine where molecular biology and advanced technologies provide crucial genomic information that can be used for better prediction outcome and targeted treatment. Personalized medicine and genomic testing drive positive impacts on the outcomes for the patients by improving treatment efficacy, providing greater insight to the disease and reducing the cost of healthcare by guiding better directed treatments.
"Roche Servicios has had a great experience working with CGI. On one side, since the beginning, they understood our needs and requirements and most importantly consistently delivered the service we required. Moreover, together we have been able to add and improve the processes to meet our customer needs, allowing us to offer high quality results and in a very short time to our patients," mentioned Alvaro Soto, Roche Central America and the Caribbean's General Manager. "This commitment with Roche's vision and values to offer to patients the best service to improve their lives, has made CGI a true business partner for Roche Servicios, SA," added Soto.
Commenting on the partnership, Panna Sharma, CEO and President of CGI, says, "Partnering with Roche Servicios is an important element of placing genomic and state-of-the-art biomarker based cancer testing into the community. Genomics will drive change in patient quality and healthcare costs by being incorporated globally into the routine testing paradigm, and with a partner like Roche we have the opportunity to make a significant impact. We share the same philosophy of placing the patients' interest first."
CGI will initially target testing for solid tumors and will work in close conjunction with Roche for expansion into other oncology categories.
Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited and GLP compliant. In addition we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey. The company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, as well as strong research collaborations with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute.
CGI's dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new tests. CGI's full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.
For further information, www.cancergenetics.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
For more information: www.roche.com.